About the Authors
- Takashi Katsura
-
Affiliation Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
- Dan Kawamori
-
* E-mail: kawamorid@endmet.med.osaka-u.ac.jp
Affiliation Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
- Eri Aida
-
Affiliation Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
- Taka-aki Matsuoka
-
Affiliation Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
- Iichiro Shimomura
-
Affiliation Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
Competing Interests
Here we declare the competing interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials, and there is no restriction on sharing of data and/or materials. T. Katsura: None. D. Kawamori: Research Support and Speaker's Bureau Astellas Pharma Inc., AstraZeneca K.K., Daiichi Sankyo Company Limited, Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Takeda Pharmaceutical Company Limited E. Aida: Employee Parexel International Inc. T. Matsuoka: Research Support and Speaker's Bureau Astellas Pharma Inc., AstraZeneca K.K., Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Company Limited I. Shimomura: Research Support and Speaker's Bureau Astellas Pharma Inc., AstraZeneca K.K., Bristol-Myers Squibb K.K., Daiichi Sankyo Company Limited, Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Shionogi & Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited
Author Contributions
Conceptualization: DK. Data curation: TK DK EA. Formal analysis: TK DK. Funding acquisition: DK TM. Investigation: TK DK EA TM. Methodology: DK TM. Project administration: DK. Resources: TK DK EA TM. Supervision: TM IS. Validation: TK DK TM. Visualization: TK DK. Writing – original draft: TK DK. Writing – review & editing: TK DK TM IS.